Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 300
- Registration Number
- NCT06744504
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 60
- Registration Number
- NCT06744556
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
- Conditions
- Interventions
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 60
- Registration Number
- NCT06050941
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06034470
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT06001788
- Locations
- 🇺🇸
The University of Kansas, Kansas City, Kansas, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Prisma Health, Greenville, South Carolina, United States
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 88
- Registration Number
- NCT05404516
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-07-27
- Target Recruit Count
- 43
- Registration Number
- NCT05313958
- Locations
- 🇨🇳
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Chen Suning
- Target Recruit Count
- 188
- Registration Number
- NCT05177731
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- LanZhou University
- Target Recruit Count
- 30
- Registration Number
- NCT05053425
- Locations
- 🇨🇳
Long Zhao, Lanzhou, Gansu, China
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 172
- Registration Number
- NCT04801797
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.